Skip to main content
Premium Trial:

Request an Annual Quote

Genetix Lays Off 10 Percent of Staff Despite Revenue, Profit Growth in 04

NEW YORK, March 1 (GenomeWeb News) - Genetix Group today said today that it has laid off around 10 percent of its staff at the end of 2004 despite a 13-percent increase in 2004 net sales and a 103-percent jump in profits.


The total number of employees let go was not immediately known.


The UK-based company said net sales for the 12 months ended Dec. 31, 2004, increased to £12.2 million ($23.4 million) from £10.8 million in 2003.


Genetix said that instrumentation sales were £9.2 million in 2004, an increase of 25 percent from 2003. Consumables and services accounted for £3 million in sales in 2004, down 14 percent from the prior year.


The company posted a pre-tax profit of £900,000 in 2004, up 103 percent from the prior year. It spent £1.5 million on R&D in 2004, up slightly from £1.4 million in the prior year.


In a statement, CEO Mark Reid said the company "began the process of strengthening our strategic focus on the cell biology market, concentrating on systems that accelerate drug target validation and product development. We believe that these areas will provide a platform for growth over the coming years."


Genetix's main product lines are the ClonePix mammalian cell colony picker; the aQuire scanner for imaging cells, tissue, and protein arrays; and the QArray and QPix microarrayer products.


The company finished 2004 with a cash balance of £22.2 million.


Genetix Group is headquartered in New Milton, UK, and its stock is traded on the London Stock Exchange.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.